Gene Biotherapeutics, Inc.
CRXM · OTC
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$652 | $779 | -$553 | -$2,097 |
| Dep. & Amort. | $2 | $58 | $63 | $66 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $0 | $0 | $1 |
| Change in WC | $180 | -$568 | $618 | $807 |
| Other Non-Cash | -$663 | -$407 | -$580 | $160 |
| Operating Cash Flow | -$1,133 | -$137 | -$452 | -$1,062 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$3 | $0 | $0 | $0 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | $0 | $0 | $0 | $0 |
| Inv. Sales/Matur. | $0 | $0 | $0 | $0 |
| Other Inv. Act. | $0 | $0 | $650 | $0 |
| Investing Cash Flow | -$3 | $0 | $650 | $0 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$11 | $55 | -$165 | $181 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $1,533 | $0 | $0 | $0 |
| Financing Cash Flow | $1,522 | $55 | -$165 | $181 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $386 | -$82 | $33 | -$881 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $0 | $82 | $49 | $930 |
| End Cash | $386 | $0 | $82 | $49 |
| Free Cash Flow | -$1,136 | -$137 | -$452 | -$1,062 |